AstraZeneca's Imfinzi (durvalumab) Receives MHLW's Approval for Extensive-Stage Small Cell Lung Cancer
Shots:
- The approval is based on P-III CASPIAN study assessing Imfinzi + etoposide and either carboplatin/ cisplatin CT or Imfinzi & CT+ tremelimumab vs CT as monothx. as 1L treatment in 805 patients with ES-SCLC. The trial used an FD of Imfinzi (1-500mg- q3w for 4 cycles) while in combination with CT and then q4w until disease progression
- Results: the study met its 1EPs of OS in Jun’2019- demonstrated a 27% reduction in risk of death with m-OS (13.0 vs 10.3 mos.); ORR (68% vs 58%). An updated analysis demonstrated sustained efficacy after a median follow up 2+ yrs.- m-OS (12.9 vs 10.5 mos.)
- Imfinzi is a mAb targeting PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80- countering the tumor's immune-evading tactics and releasing the inhibition of immune responses
Ref: AstraZeneca | Image: Clinical Lab Products
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com